Daily Target 2X Long LMND ETF
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management - Leveraged
- Address
- 4350 La Jolla Village Drive, Suite 670 San Diego CA United States of America 92122
- IPO Date
- Oct 16, 2025
- Website
- defianceetfs.com
- Similar Companies
- Business
- Luminex Corporation, a biotechnology company and subsidiary of DiaSorin S.p.A., develops, manufactures, and markets proprietary biological testing technologies and products with applications in clinical diagnostics, pharmaceutical research and development, genomic and proteomic research, biomedical research, food safety, and bio-defense. The company offers xMAP multiplexing technology platforms including the Luminex 100/200 and FLEXMAP 3D systems that integrate fluidics, optics, and digital signal processing for high-throughput analysis of proteins and nucleic acids; the MAGPIX multiplexing analyzer for qualitative and quantitative assays; VERIGENE semi-automated molecular diagnostic system and test cartridges; flow cytometry instruments such as Amnis FlowSight, ImageStream Mark II, CellStream, Guava easyCyte, and Muse cell analyzers; proprietary microspheres including MicroPlex, MagPlex, xTAG, and SeroMAP; xPONENT software for instrument control, data analysis, and workflow optimization; and TDAS analysis software for nucleic acid assay development, complemented by maintenance support plans and custom assay services through LuminexPLORE Lab. Luminex Corporation was founded in 1995 and is headquartered in Austin, Texas, with additional facilities in Northbrook, Illinois; Madison, Wisconsin; Seattle, Washington; ‘s-Hertogenbosch, the Netherlands; Shanghai, China; Kowloon, Hong Kong; Tokyo, Japan; and Toronto, Canada, serving global markets in healthcare, life sciences, public health, academic research, biopharma, and applied technologies such as transplant, autoimmune, infectious diseases, oncology, allergy, microbiome, food testing, drug discovery, and disease surveillance. In 2022, DiaSorin completed its acquisition of Luminex for USD 37 per share in a USD 1.8 billion all-cash transaction, integrating Luminex's multiplexing portfolio to expand DiaSorin's molecular diagnostics and life sciences offerings, particularly in the United States; recent developments include the May 2024 launch of the MAGPIX 2.0 system and new bead-based assays for cancer diagnostics and immune profiling, alongside partnerships with AI firms for precision medicine data analysis.
Defiance Launches LMNX: The First 2X Long ETF for Lemonade, Inc.
Luminex Corporation Declares Second Quarter Cash Dividend
DiaSorin: Surfing The COVID-19 Wave, Culminating In A $1.8 Billion Acquisition Of Luminex
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Luminex Corp. - LMNX
LUMINEX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Luminex Corporation - LMNX
Strength Seen in Luminex (LMNX): Can Its 12.4% Jump Turn into More Strength?
INVESTIGATION ALERT: Halper Sadeh LLP Investigates LMNX, NUAN, CADE, GNMK; Shareholders are Encouraged to Contact the Firm
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Luminex Corporation
Italian Diagnostic Developer Calls Luminex a 'Perfect Fit'
SHAREHOLDER ALERT: WeissLaw LLP Investigates Luminex Corporation
Shareholder Alert: Ademi LLP investigates whether Luminex Corporation has obtained a Fair Price in its transaction with DiaSorin
LMNX Stock: Over 9% Increase Pre-Market Explanation
DiaSorin to acquire U.S.-based Luminex for around $1.8 billion
Here's Why You Should Retain Luminex (LMNX) Stock for Now
Olink Holding Pursues $300 Million U.S. IPO Effort
Luminex (LMNX) Files EUA Application for New Respiratory Assay
Luminex (LMNX) Up 14.4% Since Last Earnings Report: Can It Continue?
Luminex Submits Joint SARS-CoV-2 and Flu/RSV Respiratory Panel to FDA for Emergency Use Authorization
Luminex (LMNX) Surges 6.3%: Is This an Indication of Further Gains?
Luminex Receives FDA Emergency Use Authorization and CE Mark for Expanded NxTAG® Respiratory Panel Test Including SARS-CoV-2